Regeneron Pharmaceuticals Inc
The Top Pharma List rankings are compiled from GlobalData’s pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. Listed below are the charts and positions for Regeneron Pharmaceuticals Inc in this year’s pharmaceutical sales data alongside recent articles on PMLiVE featuring Regeneron Pharmaceuticals Inc.
Recent articles on PMLiVE featuring Regeneron Pharmaceuticals Inc
Phase 3 trial results showed the drug significantly improved disease-free survival
More than 36,000 new cases of the blood cancer are expected to be diagnosed in the US this year
The candidate is being evaluated in a phase 3 obesity trial and phase 2b diabetes study
The agreement comes two months after 23andMe filed for bankruptcy protection
More than 35,000 new cases of the blood cancer are diagnosed in Europe every year
More than 35,000 new cases of the blood cancer are diagnosed every year in Europe
Paroxysmal nocturnal haemoglobinuria affects up to 1.5 people per million in the US
Non-small cell lung cancer accounts for up to 85% of all lung cancer cases
Follicular lymphoma and diffuse large B-cell lymphoma are collectively responsible for an estimated 283,000 global cases every year
The companies will aim to develop CRISPR-based therapies for multiple tissues and cell types
Patients aged eight year or older with heterozygous familial hypercholesterolaemia will be eligible to receive the treatment
The regulator is expected to make a decision on the drug by the end of March 2024
Data provided by GlobalData
GlobalData provides trusted intelligence on the world’s largest industries including Pharmaceutical and Medical Devices. With over 2,000 in-house experts, our data-driven, technology-powered approach delivers gold-standard insights to help businesses navigate complex markets and predict future trends.
Our integrated platform empowers 4,000 of the world’s largest companies—including over 70% of FTSE 100 and 60% of Fortune 100 firms—to make timely, informed decisions through unique data, expert analysis, and innovative consulting solutions.
To find out more about how our research and insights can help you, please visit https://www.globaldata.com/who-we-are/why-globaldata/
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE’s Top Pharma List – Methodology